Cambrex Takes Major Steps in Expanding US and European Manufacturing Capacities

Cambrex Enhances Production Capacities in the USA and Europe

Cambrex, a prominent global contract development and manufacturing organization (CDMO), is making significant strides in its expansion plans across the USA and Europe. Recently, the company announced the successful completion of initial engineering studies for its new pharmaceutical active ingredient (API) production facility located in Charles City, Iowa. This milestone represents a critical step forward in Cambrex's $120 million investment aimed at bolstering its manufacturing capabilities within the United States.

The groundbreaking for this state-of-the-art facility is scheduled for the end of 2026, featuring a remarkable production capacity of 140,000 liters. The design of the site includes large and medium reactor systems, modern Hastelloy stirring filter driers, and upgrades to the existing production facilities. Once the construction is completed, the site is expected to increase its large-scale production capacity by 20%. This expansion aims to support complex chemical processes such as the manufacturing of controlled substances, highly potent active pharmaceutical ingredients (HPAPI), and large-scale peptide manufacturing, thereby establishing Cambrex as a dependable partner for pharmaceutical innovators.

Aside from the initiatives in the United States, Cambrex is also expanding its manufacturing site in Milan, Italy, where a further investment of $30 million has been allocated. This project is set to enhance capacity for analytical development and process research, alongside several modernized manufacturing facilities. Notably, the research and development site in Milan is expected to be completed in the latter half of 2027. To facilitate future growth and meet the rising demand for CDMO services, additional land has been acquired.

Claudio Russolo, Chief Operating Officer of Cambrex, highlighted the site's remarkable history, stating, “Our Milan facility has a long-standing tradition in supporting pharmaceutical development and manufacturing, celebrating its 80th anniversary this year. We remain committed to investing to meet the growing market demand for complex chemical ingredients, including Tides, highly potent molecules, and controlled substances.”

Cambrex's ongoing investments symbolize the company's dedication to providing cutting-edge solutions for the development and manufacturing of active ingredients and complex low molecular weight compounds. Their science-driven approach and commitment to operational excellence ensure that Cambrex continues to play a leading role in the development of next-generation life-changing therapies.

With 45 years of experience and a growing team of over 2,000 experts serving clients in North America and Europe, Cambrex’s services span the entire lifecycle of drug development. The company offers a diverse range of specialized manufacturing technologies, including continuous flow technology, controlled substances, peptide synthesis, solid-state science, and material characterization. Cambrex is well-equipped to meet the evolving needs of the pharmaceutical industry as it advances its capabilities to support innovative therapies.